HRAS and neoplasm: A recent review article has listed a collection of studies reporting genes and their occurrences of mutations in angiosarcoma tumor tissues, such as KDR (the gene was mutated in 5.9–7% of analyzed tumor samples), PLCG1 (2.9–20%), PTPRB (17.6–25.6%), KRAS (2.6–2.9%), HRAS (5.5–11.8%), NRAS (5.5–5.9%), BRAF (11.8%), MAPK1 (2.9%), NFL1 (2.6–2.9%), PI3KCA (2.6–16.7%), TP53 (4–35%), CIC (2–6%), ROS1 (3%), and CDKN2A (26.5%), as summarized in [296].